Related Experiment Videos
High-affinity partial agonists of the vanilloid receptor
Yun Wang1, Attila Toth, Richard Tran
1National Cancer Institute, Building 37, Room 4048, 37 Convent Drive MSC 4255, Bethesda, MD 20892-4255, USA.
Molecular Pharmacology
|July 19, 2003
Summary
Two novel compounds, JYL827 and JYL1511, act as potent partial agonists for the vanilloid receptor VR1. Their efficacy is modulated by factors like pH, temperature, and PKC, suggesting context-dependent biological behavior for pain management therapies.
Area of Science:
- Pharmacology
- Neuroscience
- Molecular Biology
Background:
- The vanilloid receptor 1 (VR1) is a key target for pain and bladder hyperreflexia therapies.
- Developing novel VR1 ligands with improved potency and unique properties is crucial.
Purpose of the Study:
- To characterize two novel thiourea compounds, JYL827 and JYL1511, as partial agonists of rat VR1.
- To investigate the influence of co-activators on the partial agonism of these compounds.
Main Methods:
- Heterologous expression of rat VR1 in Chinese hamster ovary cells.
- Assays for [3H] resiniferatoxin binding and 45Ca2+ uptake.
- Evaluation of compound potency, partial agonism, and antagonism.
- Assessment of modulation by protons, temperature, and protein kinase C.
Main Results:
- JYL827 and JYL1511 demonstrated significantly higher potency than capsaicin for [3H] resiniferatoxin binding.
- Both compounds exhibited partial agonism, with varying degrees of partial antagonism.
- Protons, temperature, and PKC enhanced the partial agonism of JYL827 and JYL1511, particularly at acidic pH.
Conclusions:
- JYL827 and JYL1511 are potent partial agonists of rat VR1 with distinct pharmacological profiles.
- The biological activity of these partial agonists is strongly dependent on VR1 modulators, highlighting the importance of biological context.
- These compounds offer new avenues for exploring VR1-targeted therapies in preclinical models.